r BioReference PRELIMINARY

r BioReference PRELIMINARY LABORATORIES D 0 T C R FISCH, HARRY C1720 - HARRY FISCH, III. 944 PARK AVENUE, NEW YORK, NY 10028 Acct #: (C1720) P: (212)879-0800 S1 lI Rm: EPSTEIN, JEFFREY P BOB: 01/20/1953 Age: 62 y Sex: M A U/FL: Bed: Patient ID: T E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 p: (212)772-9416 1 Specimen ID: 100820998 Date Of Report: 10/29/2015 09:10 Date Collected: 10/27/2015 16:44 Date Received: 10/27/2015 22:29 North America Eastern Time LNotes: NON FASTING CLINICAL REPORT Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.) Cholesterol 210 HI HDL as % of Cholesterol 14 • VLDL, CALCULATED PT Blood, Urine TESTOSTERONE, TOT.,S. Hemoglobin A1C 70 HI 10.0 LO SMALL * 112.3 LO 5.9 HI Triglycerides LDL/HDL Ratio 348 HI HDL CHOL., DIRECT 29 LO 3.83 HI LDL Cholesterol 111 HI INTR.NORM.RATIO(INR) 0.92 LO FREE TESTOSTERONE 29.82 LO PROLACTIN, SERUM 3.4 LO • 1 Test Result Abnormal e erence n s rev ous esu a e Total Protein 7.1 5.9-8.4 g/dL Albumin 4.6 3.5-5.2 g/dL Globulin 2.5 1.7-3.7 g/dL AA Ratio 1.8 1.1-2.9 Glucose 95 70-99 mg/dL Sodium 135 133-145 mmol/L Potassium 4.2 3.3-5.3 mmol/L Chloride 96 96-108 mmol/L CO2 26 22-29 mmol/L BUN 21 8-23 mg/dL Creatinine 1.03 0.80-1.30 mg/dL e-GFR 77 >or=60 mL/min e-GFR, African American 89 >or=60 mL/min BUN/Creat Ratio 20.4 10.0-28.0 Calcium 9.7 8.6-10.4 mg/dL Uric Acid 6.2 3.4-8.5 mg/dL Iron 57 45-160 ug/dl Bilirubin, Total 0.5 <1.2 mg/dL LD 177 135-225 U/L Alk Phos 62 40-156 U/L AST 23 <40 U/L PHOSPHORUS 3.3 2.7-4.5 mg/dL ALT 25 <41 U/L GGTP 15 10-71 U/L -* CARDIOVASCULAR/LIPIDS *-- Cholesterol 210 HI <200 mg/dL Triglycerides 348 HI <150 mg/dL BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N) 07407 I (800) 229-5227 JamesWolsberger.. Page 1 of S Laboratory Director Printed 11/02/2015 12:27 EFTA00594095 BioReference --tstr LABORATORIES D 0 C R FISCH, HARRY C1720 - HARRY FISCH, III. 944 PARK AVENUE, NEW YORK, NY 10028 Acct #: (C1720) P: (212)879-0800 S1 EPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 62 y Sex: M A U/FL: Bed: T Rm: I Patient ID: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 T P: (212)772-9416 IPRELIMINARY Specimen ID: 100820998 Date Of Report: 10/29/2015 09:10 Date Collected: 10/27/2015 16:44 Date Received: 10/27/2015 22:29 North America Eastern Time CLINICAL REPORT Test • Result Abnormal Reference Units Previous Result Date HDL CHOL., DIRECT 29 LO >40 mg/dL HDL as % of Cholesterol 14 * >14 % Evaluation: ABOVE AVG.(MODERATE RISK) Chol/HDL Ratio 7.2 <7.4 1 Evaluation: AVERAGE RISK LDL/HDL Ratio 3.83 HI <3.56 LDL Cholesterol 111 HI <100 mg/dL VLDL, CALCULATED 70 HI 7-32 mg/dL * HEMATOLOGY * WBC 6.33 3.40-11.80 x10(3)/uL RBC 5.01 4.20-5.90 x10(6)/uL HGB 14.6 12.3-17.0 gm/dL HCT 41.9 39.3-52.5 MCV 83.6 80.0-100.0 fL MCH 29.1 25.0-34.1 pg MCHC 34.8 29.0-35.0 gm/dL RDW 14.4 10.9-16.9 % POLYS 51.1 36.0-78.0 % LYMPHS 37.1 12.0-48.0 % MONOS 5.8 0.0-13.0 EOS 5.4 0.0-8.0 % BASOS 0.6 0.0-2.0 % IMMATURE GRANULOCYTES 0.0 0.0-1.6 % Platelet Count 257 144-400 x10(3)/oL MPV 9.0 8.2-11.9 fL PT 10.0 LO 10.3-12.8 sec INTR.NORM.RATIO(INR) 0.92 LO 2.00-3.00 CLINICAL INDICATIONS FOR INK USE Prophylaxis or treatment of venous thrombosis, systemic embolization, and pulmonary embolus High-risk patients with mechanical heart valves Normal Non-Medicated patients NOTE: INR values below 2.00 for patients on warfarin therapy would be considered sub-therapeutic for the above conditions. Reference Range 2.00-3.00 2.50-3.50 0.87-1.19 PIT 27.6 23.6-31.6 sec I [ BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N2 07407 I (800) 229-5227 Page 2 of 5 JannesiNekbergerIll. Laboratory Director Printed 11/02/2015 12:27 EFTA00594096 BioReferencer LABORATORIES 0 C R FISCH, HARRY C1720 - HARRY FISCH, III. 944 PARK AVENUE, NEW YORK, NY 10028 Acct #: (C1720) P: (212)879-0800 51 EPSTEIN, JEFFREY P DOB: 21:20/1953 Age: 62 y Sex: M A U/FL: Bed: I Rm: I Patient ID: E Address: 9 EAST 71ST STREET, N NEW YORK, NY 10021 I P: (212)772-9416 PRELIMINARY 1 Specimen ID: 100820998 Date Of Report: 10/29/2015 09:10 Date Collected: 10/27/2015 16:44 Date Received: 10/27/2015 22:29 North America Eastern Time CLINICAL REPORT Test Result Abnormal Reference m Units Previous Result Date * URINALYSIS * Color YELLOW YELLOW, STRAW, AMBER Character CLEAR CLEAR Specific Gravity URN 1.023 1.003 - 1.030 pH Urine 5.0 5.0 - 8.0 Protein, Urine NEGATIVE NEGATIVE Glucose, Urine NEGATIVE NEGATIVE Ketone, Urine NEGATIVE NEGATIVE Urobilinogen Urine 0.2 0.2 - 1.0 Units Bilirubin, Urine NEGATIVE NEGATIVE Blood, Urine SMALL * NEGATIVE Nitrites Urine NEGATIVE NEGATIVE Leukocyte Esterase NEGATIVE NEGATIVE Crystals Urine NONE NONE Crystal Amt. Urine NONE NONE WBC, Urine 0-4 0-4 PER HPF RBC, Urine NONE SEEN NONE SEEN PER HPF Epithelial Cells, Ur NONE FEW Cast, Hyaline, Urine 0-4 0-4 PER LPF Cast, Granular, Urin NONE SEEN 0-1 PER LPF Cast, RBC, Urine NONE SEEN 0-1 PER LPF Bacteria, Urine NONE FEW * MICROBIOLOGY * CULTURE, URINE <10,000 NO GROWTH CFU/ML (U... <10,000 CFU/ML (USUALLY CONSIDERED INSIGNIFICANT GROWTH) SOURCE: URINE * MISCELLANEOUS * TSH 2.060 0.178-4.530 uIU/mL THYR0XINE(T4) 7.5 4.9-12.9 ug/dL T3 UPTAKE (T3U) 29.1 24.3-39.0 % THYROXINE, FREE (FT4) 1.06 0.80-1.73 ng/dL FREE T4 INDEX 2.2 1.5-3.8 T3 (THYRONINE), TOTAL 129 72-180 ng/dL PSA Total 0.87 <4.00 ng/mL NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N3 07407 I (800) 229-5227 JarnesWelsbergerIll. Page 3 of 5 Laboratory Director Printed 11/02/2015 12:27 EFTA00594097 BioReference LABORATORIES D 0 T C R FISCH, HARRY C1720 - HARRY FISCH, III. 944 PARK AVENUE, NEW YORK, NY 10028 Acct #: (C1720) P: (212)879-0800 S1 EPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 62 y Sex: M A U/FL: Bed: T Rm: I Patient ID: E Address: 9 EAST 71ST STREET, N NEW YORK, NY 10021 T P: (212)772-9416 PRELIMINARY 1 Specimen ID: 100820998 Date Of Report: 10/29/2015 09:10 Date Collected: 10/27/2015 16:44 Date Received: 10/27/2015 22:29 North America Eastern Time CLINICAL REPORT Test Result Abnormal Reference m Units I Previous Result' Date based solely upon values obtained from serial P5A values obtained on the patient. NOTE: Values obtained with different assay methods or kits cannot be used interchangeably. NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). PSA, FREE 0.31 Not Estab. ng/mL I NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). % FREE PSA 36 See Below % I FREE PSA RISK ASSESSMENT The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below: PROBABILITY OF CANCER* %free PSA (50-59 yrs) (60-69 yrs) (>or.70 yrs) cor•10 49.2% 57.5% 64.5% 11-18 26.9% 33.9% 40.8% 19-25 18.3% 23.9% 29.7% >25 9.1% 12.2% 15.8% *probability of finding prostate cancer by needle biopsy NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E170 immunoassay system.(02/2012;v5) TESTOSTERONE, TOT.,S. 112.3 LO 193.0-740.0 ng/dL TESTOSTERONE, BIOAVAIL. 74.6 72.0-460.0 ng/dL SEX HORM.BIND.GLOB. 14 10-57 nmol/L FREE TESTOSTERONE 29.82 LO 30.00-150.00 pg/mL LH 3.7 1.7-8.6 mIU/mL FSH 4.0 1.5-12.4 mIU/mL PROLACTIN, SERUM 3.4 LO 4.0-15.2 ng/mL ESTRADIOL 16.00 7.02-49.06 pg/mL FIBRINOGEN 362 176-441 mg/dL Hemoglobin A1C 5.9 HI <5.7 % HEMOGLOBIN A1c AND eAG REFERENCE RANGES A1c(%) DIABETES CATEGORY* <5.7 Normal (non-diabetic) 5.7-6.4 Increased risk of diabetes BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N) 07407 I (800) 229-5227 Page 4 of 5 Jarnes‘VMsbergerIll. Laboratory Director Printed 11/02/2015 12:27 EFTA00594098 BioReference D LABORATORIES T C R FISCH, HARRY C1720 - HARRY FISCH, III. 944 PARK AVENUE, NEW YORK, NY 10028 Acct #: (C1720) P: (212)879-0800 S1 ITEPSTEIN, JEFFREY P DOB: 01/20/1953 Age: 62 y Sex: M U/FL: Bed: T Rm: I Patient ID: E Address:9 EAST 71ST STREET, N NEW YORK, NY 10021 P: (212)772-9416 PRELIMINARY 1 Specimen ID: 100820998 Date Of Report: 10/29/2015 09:10 Date Collected: 10/27/2015 16:44 Date Received: 10/27/2015 22:29 North Americo Eastern Time CLINICAL REPORT Test Result Abnormal Reference Units [Previous Result Date NOTE: .>6.5 Consistent with A1c(%) eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL) 6 126 7 154 8 183 9 212 10 240 11 269 diabetes 12 298 *recommended ranges -American Diabetes Association(2010) Hemolysis, rare hemoglobin variants and thalassemia major may affect glycemic results. DIHYDROTESTOSTERONE TO FOLLOW SEE REPORT BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N) 07407 I (800) 229-5227 Page S of 5 JarnesiNelsbergerilli Laboratory Director printed 11/02/2015 12:27 EFTA00594099